AN2 Therapeutics, Inc.
ANTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $32 | $41 | $41 |
| - Cash | $18 | $18 | $20 | $21 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $14 | $21 | $20 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$9 | -$7 | -$12 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$9 | -$6 | -$11 | -$8 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.31 | -0.21 | -0.35 | -0.25 |
| % Growth | -47.6% | 40% | -40% | – |
| Operating Cash Flow | -$6 | -$8 | -$11 | -$5 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6 | -$8 | -$11 | -$5 |